Correction: The insoluble excretion of multi-matrix system mesalazine preparations in patients with ulcerative colitis
Main Authors: | Yuichiro Ohtaki, Kan Uchiyama, Hirotaka Kamiya, Eri Moriizumi, Moe Yamada, Yuma Aoki, Toshimune Watanabe, Sachie Kiryu, Shizuka Suzuki, Yoshihiro Matsumoto, Zensho Ito, Toshifumi Ohkusa, Shigeo Koido, Masayuki Saruta |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-02-01
|
Series: | BMC Gastroenterology |
Online Access: | https://doi.org/10.1186/s12876-022-02608-z |
Similar Items
-
Analysis of the NUDT15 gene and metabolites of azathioprine in Japanese patients with inflammatory bowel disease
by: Shizuka Suzuki, et al.
Published: (2023-07-01) -
Metagenomic analyses of the gut microbiota associated with colorectal adenoma.
by: Keisuke Saito, et al.
Published: (2019-01-01) -
Dysbiosis of the Fecal and Biliary Microbiota in Biliary Tract Cancer
by: Zensho Ito, et al.
Published: (2022-10-01) -
Comparison of efficacy of multimatrix mesalazine 4.8 g/day once-daily with other high-dose mesalazine in active ulcerative colitis: a randomized, double-blind study
by: Haruhiko Ogata, et al.
Published: (2017-07-01) -
MESALAZINE PLACE IN THERAPY OF ULCERATIVE COLITIS
by: I. G. Bakulin, et al.
Published: (2017-11-01)